Talking Fast-Track Designation and Drug Development with Dr Courtney DiNardo

In a new interview with AJMC, Courtney DiNardo, MD, MSCE, of the University of Texas MD Anderson Cancer Center detailed how FDA fast track designation can help with the drug development process. She argues that it can help guide trial development in ways that align with agency preferences and priorities. In addition, she spoke about patient recruitment and retention.

According to DiNardo, “Here, trying to improve recruitment is a really important goal. And I think actually one of the very few silver linings of the COVID-19 pandemic was the ability of creating just better networks across the country of telemedicine, of making different people … and community settings aware of different trials that are available, and hopefully making access easier for patients that otherwise wouldn’t be going to a major center. So, I think one of the most important things is awareness so that people, patients, family members, and community oncologists are aware of different trials and then, it’s the actual process of getting the patient to where the trial is open.”

To read more, click here.

(Source: AJMC, June 11^th, 2023)